Relief Therapeutics Holding AG (RLFTF)

[tcm55]

9-24-20, yes with only 51 total patients at that time it was too early for this application. But the World was on Fire and they Tried.
NOW with several hundred treated through the EAP program AND met secondary endpoints in the COVID Phase2/3 Trial AND now having much more general Data supporting the Lung healing results for NRX/RLF/RLF-100 in the IV form.
I think this current EUA should have a much stronger application.
The UC/St jude Inhaler Trial should have filled fast and could have Interim results and supplemental data to the IV form of RLF-100.



'Relief Therapeutics and NeuroRx have applied to the FDA for an Emergency Use Authorization (EUA) for RLF-100 (aviptadil) for the treatment of critical COVID-19 patients with respiratory failure.

Aviptadil is a synthetic form of a natural peptide that blocks replication of the SARS-CoV-2 coronavirus in human lung cells and immune cells. "The agency previously granted Aviptadil an Orphan Drug designation for treatment of acute respiratory distress syndrome".

""The EUA application was based on a study of 51 patients"", in which those treated with Aviptadil demonstrated a three-fold increase in survival, recovery from respiratory failure and improvement in other clinical measures compared to those receiving the standard of care.

"""The emergency use request targets the same critically ill population that the FDA allowed to receive the drug under an expanded access protocol."""!!!"


https://www.fdanews.com/articles/199199-relief-therapeutics-and-neurorx-seek-eua-for-covid-19-treatment


Drop the P and GO NRLA...GLTA...

Aviptadil IV and Inhaler
USD MSU D(sodium phenylbutyrate)
Emetine
ASIB and PTSD